Resource Centre


11C-choline versus 68Ga-PSMA PET/CT scan for the detection of nodal recurrence from prostate cancer: Results from a large, multi-institutional salvage lymph node dissection series


Fossati N.1, Briganti A.1, Gandaglia G.1, Suardi N.1, Colicchia M.2, Karnes J.2, Haidl F.3, Porres D.3, Pfister D.3, Heidenreich A.3, Herlemann A.4, Gratzke C.4, Stief C.4, Battaglia A.5, Everaerts W.5, Joniau S.5, Van Poppel H.5, Aksenov A.6, Osmonov D.K.6, Jünemann K.P.6, Abreu A.D.L.8, Almeida F.8, Fay C.7, Gill I.7, Mottrie A.M.9, Montorsi F.1


1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Mayo Clinic, Dept. of Urology, Rochester, Minnesota, United States of America, 3University of Cologne, Dept. of Urology, Cologne, Germany, 4Ludwig-Maximilians-University Munich,, Dept. of Urology, Munich, Germany, 5University Hospitals Leuven, Urology, Dept of Development and Regeneration, Leuven, Belgium, 6University Hospital Schleswig Holstein, Dept. of Urology and Pediatric Urology, Campus Kiel, Germany, 7Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern Cal, USC Institute of Urology, Los Angeles, California, United States of America, 8Phoenix Imaging Center, Dept. of Urology, Phoenix, Arizona, United States of America, 9OLV Ziekenhuis Aalst, Belgium ORSI Academy, Dept. of Urology, Melle, Belgium

Introduction & Objectives

Positron emission tomography/computed tomography (PET/CT) scan with 11C-choline or 68Ga-prostate-specific-membrane-antigen (PSMA) ligand is currently used to diagnose nodal recurrence of prostate cancer. However, no previous study directly compared these two tracers in men receiving salvage lymph node dissection (SLND).

Material & Methods

The study included 266 patients affected by a single nodal recurrence that were treated with SLND at eight tertiary referral centres. All patients were diagnosed with PET/CT scan using either 11C-choline (n=196; 74%) or 68Ga-PSMA ligand (n=70; 26%). The study outcomes were the following: (i) rate of negative histologic report at final pathology; (ii) concordance between site of positive imaging and location of positive nodes (iii) biochemical response (BR) defined as PSA ≤0.2 ng/ml at one month after SLND.


Median PSA level at SLND was lower in patients diagnosed with PSMA-ligand (2.2 vs. 1.5 ng/ml, p=0.011). The single positive spot at pre-operative imaging was pelvic and retroperitoneal in 178 (91%) and 18 (9%) patients diagnosed with 11C-choline, versus 62 (89%) and 8 (11%) patients diagnosed with PSMA ligand (p=0.6). In the 11C-choline group, 41 out of 178 (23%) patients with a single pelvic spot received also retroperitoneal SLND, compared to 21 out of 62 (34%) patients in the PSMA group. In the 11C-choline group 12 out of 18 (67%) patients with a single retroperitoneal spot received also pelvic SLND, compared to 8 out of 8 (100%) patients in the PSMA group. The median number of lymph nodes removed was not significantly different (18 vs. 16, p=0.3). Overall, 50 (26%) patients diagnosed with 11C-choline and 19 (27%) patients diagnosed with PSMA had negative histologic report at final pathology (p=0.7), whereas 92 (47%) and 20 (30%) patients had ≥2 positive nodes, respectively (p=0.013). The concordance between site of positive imaging and location of positive nodes was not significantly different among groups (72% vs. 69%, p=0.3). 0verall, 93 (47%) and 23 (32%) patients had positive nodes outside the positive sites of PET/CT scan (p=0.013). However, when considering only patients with single positive spot in the pelvis, the rate of retroperitoneal positive nodes was not significantly different (12% vs. 14%, p=0.4). The BR rate was significantly higher in the PSMA group (33% vs. 43%, p=0.016).


In patients with a single positive spot at PET/CT scan, the rate of negative histology is not significantly different when 11C-choline or PSMA are used. Moreover, both ligands significantly underestimate the true nodal tumour burden. However, using PSMA ligand tracer, similar diagnostic results may be achieved at lower PSA level. Overall, our data suggest the need for extensive salvage therapies whenever SLND is indicated, regardless of the tracer used at PET/CT.

  • Type: Abstract
  • Date: 27-03-2017
  • Rating: 0,0
  • Views: 871
  • Event: 32nd Annual EAU Congress London
  • Nr: 869
  • Session: Innovations in staging of prostate cancer
  • Location: Monday, 27 March 2017, 12:15 - 13:45, Room London, North Hall (Level 1)